The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Antiviral Drug Resistance: Mechanisms and Clinical Implications
Open accessAbstract
Summary Antiviral drug resistance is an increasing concern in immunocompromised patient populations, where ongoing viral replication and prolonged drug exposure lead to the selection of resistant strains. Rapid diagnosis of resistance can be made by associating characteristic viral mutations with resistance to various drugs as determined by phenotypic assays. Management of drug resistance includes optimization of host factors and drug delivery, selection of alternative therapies based on knowledge of mechanisms of resistance, and the development of new antivirals. This article discusses drug resistance in herpesviruses and hepatitis B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
Elion, G. B., Furman, P. A., Fyfe, J. A., Miranda, P. D., Beauchamp, L., & Schaeffer, H. J. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5716 · Cited by 1,591
Infection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., & Guguen-Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,282
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802878 · Cited by 1,181
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.020 · Cited by 881
Tenney, D. J., Rose, R. E., Baldick, C. J., Pokornowski, K. A., Eggers, B. J., Fang, J., Wichroski, M. J., Xu, D., Yang, J., Wilber, R. B., et al. (2009) · Hepatology · doi:10.1002/hep.22841 · Cited by 804
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
Allen, M. I., Deslauriers, M., Andrews, W. C., Tipples, G. A., Walters, K.-A., Tyrrell, D. L., Brown, N., & Condreay, L. D. (1998) · Hepatology · doi:10.1002/hep.510270628 · Cited by 793
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401903 · Cited by 712
Lai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 564
Cited by
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Multidrug Resistance: An Emerging Crisis
Tanwar, J., Das, S., Fatima, Z., & Hameed, S. (2014) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2014/541340 · Cited by 657
Nanotechnology-based antiviral therapeutics
Chakravarty, M., & Vora, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00818-0 · Cited by 334
Caffeic Acid and Its Derivatives: Antimicrobial Drugs toward Microbial Pathogens
Khan, F., Bamunuarachchi, N. I., Tabassum, N., & Kim, Y.-M. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c07579 · Cited by 326
Metal-Based Nanoparticles for the Treatment of Infectious Diseases
Aderibigbe, B. (2017) · Molecules · doi:10.3390/molecules22081370 · Cited by 269
Trends and targets in antiviral phototherapy
Wiehe, A., O’Brien, J. M., & Senge, M. O. (2019) · Photochemical & Photobiological Sciences · doi:10.1039/c9pp00211a · Cited by 257
Popkin, D. L., Zilka, S., Dimaano, M., Fujioka, H., Rackley, C., Salata, R., Griffith, A., Mukherjee, P. K., Ghannoum, M. A., & Esper, F. (2017) · Pathogens and Immunity · doi:10.20411/pai.v2i2.200 · Cited by 123
“This definition is more stringent than that used for other influenza medications [35].”
Background
Metadata
- Authors
- Strasfeld, L., & Chou, S.
- Venue
- Infectious Disease Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 24
- Issue
- 2
- Pages
- 413-437
- ISSN
- 0891-5520 (ISSN-L)
- OpenAlex
- W2155477672
- Cited by
- 254
- References
- 85
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.